An updating map created by CBS News' data team charts the expanse of the wildfires across Southern California. The Hughes Fire, which erupted in northwest L.A. County on Wednesday, Jan. 22 ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of ...

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova Pfizer Inc. plans to spend ...

Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. Ready to turn the market’s comeback into steady cash flow?

CUSTOMIZE THEM FOR YOUR NEIGHBORHOOD. 501 BREAKING NEWS INTO OUR NEWSROOM THIS MORNING. WE’VE LEARNED OVERNIGHT THAT TWO STUDENTS AT UW PLATTEVILLE ARE DEAD. THE CAMPUS IS IN SOUTHWEST WISCONSIN ...

GROTON, CT (WFSB) - A fire broke out early Tuesday morning at the Flagship Inn and Suites in Groton. The fire forced 20 guests out of their rooms and damaged 16 units, according to fire officials ...

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc. for the development ...

Reaction across campus was mixed. Some were preoccupied with the cancellation of final exams. Others focused on moving out and moving on. Barricades remained in place outside a door of Wilgus Hall ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Pfizer is wagering billions of dollars on a new kind of cancer immunotherapy, agreeing Monday to license a type of dual-targeting medicine that’s emerged as a must-have for drugmakers in oncology. The ...